Might Oral Human Papillomavirus (HPV) Infection in Healthy Individuals Explain Differences in HPV-Attributable Fractions in Oropharyngeal Cancer? A Systematic Review and Meta-analysis.
HPV infection
Oral
head and neck cancer
healthy population
meta-analysis
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
19 04 2019
19 04 2019
Historique:
received:
31
07
2018
accepted:
19
12
2018
pubmed:
28
12
2018
medline:
7
1
2020
entrez:
28
12
2018
Statut:
ppublish
Résumé
Differences in oral human papillomavirus (HPV) prevalence and contrasts in HPV-attributable fractions (AFs) in oropharyngeal cancer (OPC) have not been evaluated in depth. A systematic review was performed to identify studies in which at least 50 healthy individuals were tested for oral HPV infection. Information on sex, age, tobacco/alcohol consumption, sex practices, specimen collection, HPV detection, and population type was extracted. Prevalences were pooled using random-effects models for meta-analyses of binomial data. Correlations were assessed by the Spearman test. Forty-eight reports comprising 28 544 individuals fulfilled inclusion criteria. Global oral HPV prevalence was 4.9%. Estimates were highest in Europe, although regional differences were not statistically significant. HPV16 prevalence was 1.0% globally, and regional differences became statistically significant. A lifetime history of >6 sex partners showed a higher risk of oral HPV infection. The age-specific HPV distribution revealed a prevalence of ≥5% over 40 years of age and a lower prevalence at younger ages. There was no association between oral HPV prevalence and HPV-AFs or age-standardized rates (ASRs) of OPC, genital HPV in healthy women, or tobacco use. Differences in HPV-AFs or ASRs of OPC cannot be explained by differences in the prevalence of oral HPV infection across healthy populations. Consistent research on determinants of oral HPV prevalence, acquisition, clearance, and persistence is warranted.
Sections du résumé
BACKGROUND
Differences in oral human papillomavirus (HPV) prevalence and contrasts in HPV-attributable fractions (AFs) in oropharyngeal cancer (OPC) have not been evaluated in depth.
METHODS
A systematic review was performed to identify studies in which at least 50 healthy individuals were tested for oral HPV infection. Information on sex, age, tobacco/alcohol consumption, sex practices, specimen collection, HPV detection, and population type was extracted. Prevalences were pooled using random-effects models for meta-analyses of binomial data. Correlations were assessed by the Spearman test.
RESULTS
Forty-eight reports comprising 28 544 individuals fulfilled inclusion criteria. Global oral HPV prevalence was 4.9%. Estimates were highest in Europe, although regional differences were not statistically significant. HPV16 prevalence was 1.0% globally, and regional differences became statistically significant. A lifetime history of >6 sex partners showed a higher risk of oral HPV infection. The age-specific HPV distribution revealed a prevalence of ≥5% over 40 years of age and a lower prevalence at younger ages. There was no association between oral HPV prevalence and HPV-AFs or age-standardized rates (ASRs) of OPC, genital HPV in healthy women, or tobacco use.
CONCLUSIONS
Differences in HPV-AFs or ASRs of OPC cannot be explained by differences in the prevalence of oral HPV infection across healthy populations. Consistent research on determinants of oral HPV prevalence, acquisition, clearance, and persistence is warranted.
Identifiants
pubmed: 30590684
pii: 5257869
doi: 10.1093/infdis/jiy715
pmc: PMC6473173
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1574-1585Informations de copyright
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
J Clin Med Res. 2016 Oct;8(10):721-9
pubmed: 27635177
Int J Cancer. 2006 Dec 1;119(11):2620-3
pubmed: 16991119
Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2954-8
pubmed: 25205515
Am J Hum Biol. 2007 May-Jun;19(3):319-26
pubmed: 17421001
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
JAMA. 2014 Jan 8;311(2):183-92
pubmed: 24399557
J Infect Dis. 2017 Sep 1;216(5):604-611
pubmed: 28931221
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
NCHS Data Brief. 2017 Apr;(280):1-8
pubmed: 28463105
Int J Cancer. 2012 Nov 1;131(9):1969-82
pubmed: 22623137
JAMA Oncol. 2016 May 1;2(5):599-606
pubmed: 26794505
Oral Oncol. 2017 Mar;66:52-57
pubmed: 28249648
Ann Oncol. 2017 Dec 1;28(12):3065-3069
pubmed: 29059337
J Infect Dis. 2016 Jun 15;213(12):1893-6
pubmed: 26908748
Vaccine. 2010 Apr 26;28(19):3269-72
pubmed: 20226244
Head Neck. 2013 May;35(5):747-55
pubmed: 22267298
J Natl Cancer Inst. 2016 Jan 28;108(6):djv403
pubmed: 26823521
J Clin Oncol. 2015 Oct 10;33(29):3235-42
pubmed: 26351338
J Natl Cancer Inst. 2003 Dec 3;95(23):1772-83
pubmed: 14652239
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
Infect Genet Evol. 2016 Nov;45:198-204
pubmed: 27600594
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
Cancer Causes Control. 2016 Dec;27(12):1491-1498
pubmed: 27804058
Lancet. 2013 Sep 7;382(9895):877-87
pubmed: 23827089
Oral Oncol. 2018 Jul;82:91-99
pubmed: 29909908
J Gen Virol. 2017 Apr;98(4):519-526
pubmed: 28150575
Lancet. 2016 Dec 10;388(10062):e19-e23
pubmed: 27371184
Int J Epidemiol. 2010 Feb;39(1):166-81
pubmed: 20022926
Am J Epidemiol. 1994 Nov 1;140(9):783-7
pubmed: 7977288
Arch Public Health. 2014 Nov 10;72(1):39
pubmed: 25810908
J Clin Microbiol. 2005 Nov;43(11):5526-35
pubmed: 16272481
BMC Cancer. 2016 Mar 03;16:178
pubmed: 26940728
JAMA. 2012 Feb 15;307(7):693-703
pubmed: 22282321
Oral Oncol. 2014 May;50(5):364-9
pubmed: 24080455
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Acta Obstet Gynecol Scand. 2015 Mar;94(3):253-9
pubmed: 25619646
Sex Transm Dis. 2010 Jun;37(6):386-91
pubmed: 20081557
Am J Surg Pathol. 2012 Jul;36(7):945-54
pubmed: 22743284
Am J Epidemiol. 2015 Jan 1;181(1):40-53
pubmed: 25480823
J Gen Virol. 2017 Apr;98(4):681-689
pubmed: 28100295
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
Recent Results Cancer Res. 2017;206:27-35
pubmed: 27699527
Lancet Oncol. 2014 Nov;15(12):1319-31
pubmed: 25439690
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120